Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing trastuzumab emtansine (T-DM1) to the combination of trastuzumab and docetaxel in HER2-positive metastatic breast cancer was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)
• Trastuzumab emtansine (ado-trastuzumab emtansine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Metastatic Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2017-03-07